The role of MHC class II epitopes in spontaneous and therapeutic immune responses targeting liver cancer
The role of MHC class II epitopes in spontaneous and therapeutic immune responses targeting liver cancer
批准号:
495983343
负责人:
Privatdozent Dr. Thomas Wirth
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CD8 T cells are at the forefront of adaptive immunity in the battle against malignant cells. In cancer patients, however, CD8 T cells fail to eliminate cancer cells and enter a state of exhaustion that prevents cancer clearance. In this context MHC class II epitopes which activate CD4 T cells play a major role in supporting CD8 T cell immune responses and driving CD8 T cell differentiation towards an effector phenotype with potent cytolytic properties. In the absence of CD4 T cells, CD8 T cell expansion is reduced in size and poised towards a differentiation state with insufficient recall properties, termed "helpless CD8 T cells". Since the magnitude of antitumoral immune responses is in general low, the contribution of CD4 T cells to CD8 responses is harder to determine than in responses to acute infection. Recently, MHC class II epitopes have been shown to enhance CD8 T cell expansion and tumor infiltration in sarcoma. Interestingly, this effect was independent of surface MHC class II expression by the tumor. This fact implies that tumor antigens which harbor immunogenic MHC class II epitopes are taken up by dendritic cells and presented on the dendritic cells' MHC class II molecules to CD4 T cells. How CD4 T cells direct CD8 T cells towards the tumor and favor oncolysis, however, remains largely elusive. Furthermore, it remains unclear whether this role of CD4 help is specific for sarcoma or applicable to other tumor entities as well. In our research project we aim at elucidating the role of CD4 T cell help in spontaneous immune responses and immunotherapy of hepatocellular carcinoma. For this purpose, our group has developed subcutaneous and autochthonous liver cancer models, defined a number of MHC class I and II epitopes and developed several potent cellular vaccination strategies. In contrast to the data published on sarcoma, we have demonstrated elimination of liver cancer in mice using vaccinations with a single, MHC class I-specific CD8 T cell epitope in the absence of CD4 T cell help. These CD8 T cell responses were induced with a patented, heterologous cancer vaccine that employs a dendritic cell priming followed by a booster immunization with agonistic, costimulatory antibodies. Using this established prime-boost regimen we will analyze the role of CD4 T cell help in spontaneous, adaptive immune responses targeting liver cancer as well as therapeutic T cell vaccines and try to resolve the conflicting results regarding MHC class II epitopes in tumor therapy. We will furthermore extend our studies to other immunotherapies and clarify the role of MHC class II epitopes in checkpoint inhibitor therapies of hepatocellular carcinoma. Finally, using our vaccination technology we will generate a transcriptome profile of CD4 T cell help in CD8 T cells and analyze key molecules and pathways involved in CD4 T cell help.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microsphere-based glypican-3 specific immunotherapy of hepatocellular carcinoma
-
批准号:271680932
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Privatdozent Dr. Thomas Wirth
-
依托单位:
Analyse der Migration von CD8 positiven Memory T-Zellen nach wiederholter Antigenstimulation
-
批准号:164845232
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Privatdozent Dr. Thomas Wirth
-
依托单位:
Analyse der akzellerierten Entstehung von protektiven CD8+ Memory T-Zellen nach Dendritischer Zellvakzinierung bei der Immunantwort gegen Tumor und bakterielle/virale Pathogene
-
批准号:38787475
-
项目类别:Research Fellowships
-
资助金额:$0.0万
-
财政年份:2007
-
负责人:Privatdozent Dr. Thomas Wirth
-
依托单位:
国内基金
海外基金
登录
查看更多内容
MHC-I/CD14介导CD8+T细胞免疫抑制促进去势抵抗前列腺癌免疫逃逸的研究
-
批准号:2026JJ50277
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:钟上伟
-
依托单位:
去泛素化酶USP9X调控抗原呈递分子MHC-I的机制研究
-
批准号:JCZRQNB202600282
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
西黄丸通过m6A修饰介导YTHDF2/FAM13A/STUB1轴调控PCSK9-MHC-I信号逆转乳腺癌免疫逃逸的机制研究
-
批准号:2026JJ30083
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:谢小兵
-
依托单位:
BCAT2调控氨基酸代谢重编程抑制MHC-I类分子组蛋白乙酰化修饰协助免疫逃逸的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:蔡智勇
-
依托单位:
雷公藤衍生物LLDT-8通过调控NLRC5/MHC-I信号通路治疗多发性肌炎的机制研究
-
批准号:JCZRYB202500090
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
短程放疗通过IFN-β-CXCR3/MHC-II轴协同直肠癌化疗免疫治疗的分子机制研究
-
批准号:JCZRLH202500227
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
前纤维蛋白1促进MHC-I自噬性降解导致非小细胞肺癌免疫治疗耐药的机制研究
-
批准号:2025JJ50555
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:卢义晨
-
依托单位:
MHC-E限制性CD8+调节性T细胞抑制抗肿
瘤免疫反应的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:王蕾
-
依托单位:
基于ILF3-DNMT1-MHC-I途径诱导免疫逃逸探讨骨肉瘤免疫检查点抑制剂治疗原发耐药的分子机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:邹华
-
依托单位:
肿瘤相关成纤维细胞通过CNOT4/MHC-I通
路介导胰腺癌免疫逃逸的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:练国达
-
依托单位: